8-K: TScan Therapeutics Secures $52.5 Million Term Loan with Silicon Valley Bank, Refinancing Existing Debt

TScan Therapeutics has entered into a term loan agreement with Silicon Valley Bank for up to $52.5 million, replacing its existing convertible debt facility and extending the loan maturity to 2029.

Summary

• TScan Therapeutics has secured a term loan facility with Silicon Valley Bank for up to $52.5 million.
• The loan consists of a $32.5 million initial tranche, which was fully funded on December 20, 2024, and a second tranche of $20 million available at the lender's discretion until June 30, 2026.
• The initial tranche was used to refinance $17.2 million of existing debt and the remainder for general corporate purposes.
• The term loans will mature on September 1, 2029, with interest-only payments until September 30, 2027, if certain financial and clinical milestones are met.
• If the milestones are not met by June 30, 2026, the maturity date will be September 1, 2028, and the interest-only period will end on September 30, 2026.
• The interest rate is the greater of 7.00% or the prime rate minus 0.75%, capped at 9.75% per annum.
• A final payment equal to 5.0% of the original principal amount is due at maturity or upon full repayment or acceleration of the loans.
• Prepayment fees range from 1.0% to 3.0% depending on the timing of the prepayment.
• The loan agreement includes customary covenants, restrictions, and events of default, and grants the lender a first-priority security interest on substantially all of the company's assets, excluding intellectual property.

Sentiment

Score: 8

Explanation: The document is positive overall, highlighting a successful refinancing that extends the company's financial runway and avoids equity dilution. The terms of the loan are reasonable, and the management commentary is optimistic. However, the company is subject to milestones and restrictive covenants.

Positives

• The new loan extends the maturity of the debt to 2029, providing long-term financial stability.
• The interest-only period is extended to 2027 if certain milestones are met, reducing short-term cash flow pressure.
• The refinancing replaces a convertible debt facility with a non-dilutive term loan, avoiding potential equity dilution.
• The company expects its cash resources to fund its current operating plan into the fourth quarter of 2026.
• The agreement provides added financial flexibility and liquidity for TScan.

Negatives

• The company is subject to financial and clinical milestones to achieve the extended interest-only period and maturity date.
• The loan agreement includes restrictive covenants that limit the company's operational flexibility.
• The company is liable for a final payment of 5.0% of the original loan amount at maturity or upon full repayment or acceleration.
• Prepayment fees could be significant if the company chooses to repay the loan early.
• The company paid $2.1 million in exit fees and prepayment premiums to terminate the previous loan agreement.

Risks

• Failure to achieve the financial and clinical milestones by June 30, 2026, will result in a shorter maturity date and interest-only period.
• The lender has sole discretion over the availability of the second $20 million tranche.
• The loan agreement contains customary events of default that could trigger acceleration of the loan.
• The company's assets, excluding intellectual property, are pledged as collateral for the loan.
• The company is subject to restrictive covenants that limit its ability to make changes to its business, management, ownership, or business locations.

Future Outlook

TScan expects its cash resources to fund its current operating plan into the fourth quarter of 2026. The company is looking forward to working with SVB as they deliver on their critical milestones, advance their mission to bring their potential therapies to patients with cancer, and enhance shareholder value.

Management Comments

• Jason A. Amello, Chief Financial Officer, stated that the agreement allows TScan to significantly extend the interest-only period and maturity of their debt financing, providing added financial flexibility and liquidity.
• Lauren Cole, Managing Director with SVB Life Science and Healthcare Practice, expressed excitement about partnering with TScan as they advance their innovative programs.

Industry Context

This announcement reflects a common strategy for biotech companies to secure non-dilutive financing to fund operations and extend their cash runway. The deal with Silicon Valley Bank, a major player in the life sciences sector, indicates confidence in TScan's potential and programs.

Comparison to Industry Standards

• The interest rate of 7.00% or prime minus 0.75%, capped at 9.75%, is within the typical range for venture debt in the biotech industry.
• The loan structure with tranches and milestone-based terms is also common in this sector, allowing lenders to mitigate risk and companies to access capital as needed.
• The maturity date of 2029 is a positive for TScan, providing a longer runway than many similar deals.
• The use of a term loan to refinance convertible debt is a strategic move to avoid equity dilution, which is often preferred by biotech companies in early stages of development.
• Comparable companies in the biotech space often use similar financing structures, such as term loans from specialized lenders like SVB, to fund clinical trials and research and development.

Stakeholder Impact

• Shareholders benefit from the non-dilutive financing and extended cash runway.
• Employees benefit from the company's continued operations and development programs.
• Patients may benefit from the advancement of TScan's potential therapies.
• Creditors are impacted by the refinancing of the existing debt.

Next Steps

• TScan will continue to advance its hematology and solid tumor programs.
• The company will work towards achieving the financial and clinical milestones to secure the extended loan terms.
• TScan will continue to enroll patients into its clinical programs.
• The company will continue to expand its ImmunoBank.

Key Dates

Keywords

Term Loan, Refinancing, Silicon Valley Bank, Debt Financing, Biotechnology, TScan Therapeutics, Loan Agreement, Non-Dilutive Financing, Convertible Debt, Financial Milestones, Clinical Milestones